Italy Top recent stories from Italian pharma, including Angelini’s EUR 150 million EU collaboration for European health startups, Chiesi’s new deals for enzyme replacement therapies and gene editing, and why Menarini is setting its sights on the US. European Union teams up with Angelini to funnel €150M to European health…
Switzerland One in six infections worldwide is now resistant to first-line antibiotics, making antimicrobial resistance (AMR) a major global health threat. Despite an extremely challenging commercial landscape, a handful of bold startups continue to innovate in this space, but can they turn the tide? Microorganisms that develop AMR were directly…
Italy A roundup of some of the biggest pharma and healthcare stories coming out of Italy, including the country’s ever-falling birth rate; Chiesi’s new manufacturing investment; Doc Generici’s rebrand to DOC Pharma; Menarini’s oncology partnership with Insilico Medicine, and Angelini’s brain health deal with Cureverse. Italian drug maker Recordati boosts…
Switzerland The World Health Organisation has highlighted antimicrobial resistance (AMR) as one of the leading global public health and development threats today. AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to antimicrobial medicines (including antibiotics, antivirals, antifungals and antiparasitics). This makes infections harder to treat…
Switzerland Dr Daniel Roth outlines his long-standing career with Menarini Group, its strategic evolution in Switzerland, and the broader challenges facing the healthcare industry. Dr Roth emphasizes the importance of building strong teams, the role of entrepreneurial freedom in shaping local strategies, and Switzerland’s unique position in the global healthcare landscape.…
Italy Some of the biggest pharma and healthcare stories coming out of Italy, including Italy’s antitrust investigation of Novartis and Genentech; Johnson & Johnson’s EUR 125 million investment in its Italian manufacturing site; Chiesi Farmaceutici’s licensing agreement with Gossamer Bio for a pulmonary hypertension drug, and Menarini and Insilico’s oncology partnership.…
Italy A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between Venatorx Pharmaceuticals and Menarini, and the country’s drop in healthcare spending. Stevanato Group Announces Public Offering of Ordinary Shares…
India Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation. Now though, as India’s GDP and market value soar and the policy environment shifts towards prioritising the domestic development of…
India Girisan Kariangal reflects on Menarini’s journey from a primarily CSO organization to a robust branded business in India, emphasizing strategic partnerships, acquisitions, and a decisive shift towards dermatology. He outlines how Menarini positions itself as a leader in dermatology by treating dermo-cosmetics with the same rigour as pharmaceuticals and continuously…
Asia-Pacific Glen Godresse brings over 25 years of pharmaceutical industry experience to his role as Chief Marketing Officer & Head of Commercial Excellence for Menarini’s Asia-Pacific operations. In an exclusive conversation with PharmaBoardroom, he explains how Menarini Asia-Pacific is breaking the mould by focusing on niche therapeutic areas often disregarded by…
Middle East & Africa Head of the Middle East region and GM for the Middle East & Africa affiliate, Basel Thaher outlines his 18-year career at Menarini and discusses the Italian family-run company’s footprint in the region where it has a direct presence in the UAE, Saudi Arabia, Tunisia, and Egypt and plans to…
China A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR deal with SciClone Pharmaceuticals. Moderna holds onto its vaccine IP and refuses tech transfer in China (Financial Times) Moderna…
See our Cookie Privacy Policy Here
